Thursday, 21 January 2016

Glaterimer acetate during pregnacy

Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K.Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler. 2016 Jan 11. pii: 1352458515623366. [Epub ahead of print]

BACKGROUND:Only limited data are available on whether glatiramer acetate exposure during pregnancy has an effect on perinatal outcome.
OBJECTIVE:To determine the effect of glatiramer acetate exposure during pregnancy on pregnancy outcomes in women with multiple sclerosis.
METHODS:We compared the outcome of pregnancies of women with multiple sclerosis exposed to glatiramer acetate with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, labor, delivery, and outcome of pregnancy was obtained.
RESULTS: We collected data on 246 multiple sclerosis pregnancies, 151 exposed to glatiramer acetate and 95 unexposed to disease-modifying therapies during pregnancy. Three (2.2%) congenital anomalies occurred in the exposed and 6 (6.7%) in the control group. We did not observe an increase in other adverse pregnancy or delivery outcomes including spontaneous abortions, preterm birth, Cesarean sections, or reduced birth weight in the exposed group.
CONCLUSION: Our data provide further evidence that glatiramer acetate exposure during the first trimester of pregnancy appears safe and without teratogenic effect. These findings provide important additive knowledge to better counsel women with multiple sclerosis in planning a pregnancy

You can all read the conclusions. ProfG has commented many times on the value of GA during pregnancy
CoI:None

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.